Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Indiana Strombom"'
Autor:
Mark H. Gotfried, Carlos E. Girod, Danielle Antin-Ozerkis, Tracy Burgess, Indiana Strombom, John L. Stauffer, Klaus-Uwe Kirchgaessler, Maria L. Padilla
Publikováno v:
Pulmonary Therapy, Vol 4, Iss 1, Pp 59-71 (2018)
Abstract Introduction PIPF-002 was a phase 2, multicenter, open-label study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) or other types of pulmonary fibrosis (PF). PIPF-002 terminated after pirfenidone became commercially avail
Externí odkaz:
https://doaj.org/article/08433ccedbe14538acc3964d89086de2
Autor:
Vincent Cottin, Dirk Koschel, Andreas Günther, Carlo Albera, Arata Azuma, C. Magnus Sköld, Sara Tomassetti, Philip Hormel, John L. Stauffer, Indiana Strombom, Klaus-Uwe Kirchgaessler, Toby M. Maher, PASSPORT study group, Peter Cerkl, Holger Flick, Christian Geltner, Judith Löffler-Ragg, Michael Studnicka, Elisabeth Bendstrup, Helle Dall Madsen, Saher B. Shaker, Maritta Kilpelainen, Marjukka Myllaerniemi, Minna Purokivi, Seppo Saarelainen, Emmanuel Bergot, Philippe Bonniaud, Raphael Borie, Pascal Chanez, Francis Couturaud, Claire Dromer, Frederic Gagnadoux, Anne-Sophie Gamez, Anne Gondouin, Dominique Israel-Biet, Stephane Jouneau, Romain Kessler, Francois Lebargy, Sylvain Marchand-Adam, Borsi Melloni, Jean-Marc Naccache, Christophe Pison, Gregoire Prevot, Martine Reynaud-Gaubert, Abdellatif Tazi, Dominique Valeyre, Benoit Wallaert, Jost Achenbach, Stefan Andreas, Burkhard Bewig, Reiner Bonnet, Stephan Budweiser, Ulrich Costabel, Martin Faehling, Joachim Ficker, Juergen Fisher, Sven Glaeser, Christian Grah, Christian Grohe, Martin Hetzel, Wolfgang Hohenforst-Schmidt, David Jungck, Peter Kardos, Claus Keller, Martin Kohlhaeufl, Claus Kroegel, Rainer Kruegel, Berthold Michels, Joachim Mueller-Quernheim, Claus Neurohr, Heinz-Theodor Pelzer, Michael Pfeifer, Michael Prediger, Klaus F. Rabe, Winifried Randerath, Nicolas Scheonfeld, Robert Scheubel, Jens Schreiber, Hartwig Schutte, Bernd Schoenhofer, Barbara Wagener, Tobias Welte, Michael Westhoff, Heinrike Wilkens, Hubert Wirtz, Michael Henry, Michael Keane, Anthony O'Regan, Katherine O'Reilly, Fabrizio Luppi, Sandra Nutini, Alberto Pesci, Venerino Poletti, Elisabetta Rosi, Paola Rottoli, Thomas Eagan, Durdica Kulosman, Tone Blorg Sjaheim, Karl Axel Karlsson, Magnus Sköld, Sanjay Agrawal, Kesavan Suresh Babu, Stephen Bianchi, Nazia Chaudhuri, Sophie Fletcher, Michael Gibbons, Simon Hart, Gisli Jenkins, Toby Maher, Ann Millar, Joanna Porter, Nicky Simler, Lisa Spencer, Monica Spiteri, Melissa Wickremasinghe
Publikováno v:
ERJ Open Research, Vol 4, Iss 4 (2018)
Real-world studies include a broader patient population for a longer duration than randomised controlled trials (RCTs) and can provide relevant insights for clinical practice. PASSPORT was a multicentre, prospective, post-authorisation study of patie
Externí odkaz:
https://doaj.org/article/bc7d2efc99fe4cf088e6bcb6fe363782
Autor:
Robert J. Valuck, Anne M. Libby, Heather D. Anderson, Richard R. Allen, Indiana Strombom, Lauren B. Marangell, David Perahia
Publikováno v:
British Journal of Psychiatry. 208:271-279
BackgroundPlacebo-controlled clinical trials have led to concern over possible increased risk of suicide-related events in some populations exposed to antidepressants.AimsTo evaluate the risk of suicide attempts by antidepressant drug class and the p
Autor:
Vincent Cottin, Dirk Koschel, Andreas Guenther, Carlo Albera, Arata Azuma, Magnus Skold, Sara Tomassetti, Philip Hormel, John L. Stauffer, Indiana Strombom, Klaus-Uwe Kirchgaessler, Toby M. Maher
Publikováno v:
Clinical Problems.
Background: PASSPORT was a post-authorisation safety registry that collected real-world data in European patients initiating pirfenidone and patients were followed for up to 2 years. Here we present analyses at the conclusion of this 5-year study. Me
Publikováno v:
Current Drug Safety. 3:154-162
Objective: Present results from two hepatic safety studies conducted within 20 months after duloxetine launch. Methods: Signal detection based on spontaneous reports to the FDA adverse event reporting system (AERS) and on a comparison of duloxetine a
Autor:
Joachim Wernicke, Nayan Acharya, Indiana Strombom, James Gahimer, Deborah D'Souza, Natalie DiPietro, Jack Uetrecht
Publikováno v:
Current Drug Safety. 3:143-153
Objective: Review spontaneous reports and epidemiology of hepatic events associated with duloxetine. Methods: Spontaneous reports of adverse events potentially associated with hepatic injury were identified. Classification schemes were Clinical Signi
Autor:
Madelaine M. Wohlreich, Nayan Acharya, Indiana Strombom, Louis Kuritzky, Michael Robinson, Alexandra N. Heinloth, Arie Regev, Joachim F. Wernicke
Publikováno v:
Postgraduate Medicine. 120:111-118
Since its first FDA approval in 2004, duloxetine has been taken by more than 5 million patients. A small fraction of patients treated with duloxetine develop elevations in liver enzymes, which generally resolve spontaneously without any change in tre
Autor:
Stephanie A. Robert, Indiana Strombom, Amy Trentham-Dietz, John M. Hampton, Jane A. McElroy, Polly A. Newcomb, Patrick L. Remington
Publikováno v:
Epidemiology. 15:442-450
Women are at higher risk of breast cancer if they have higher socioeconomic status (SES) or live in higher SES or urban communities. We examined whether women living in such communities remained at greater risk of breast cancer after controlling for
Publikováno v:
Journal of clinical psychopharmacology. 32(1)
Cardiovascular events are inconclusively associated with duloxetine use in clinical trials and spontaneous reports. This analysis of cardiovascular events in relation to duloxetine use within a large health insurance database provides further data on
Publikováno v:
Journal of clinical psychopharmacology. 31(4)
Elevated hepatic enzyme levels and hepatic injuries have been associated with duloxetine use in clinical trials and spontaneous reports, but the association of duloxetine with a broad spectrum of hepatic outcomes has not been assessed observationally